Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03596086 · ClinicalTrials.gov registry record · Phase 1
HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM
A Phase 1 study of Glioblastoma Multiforme and Astrocytoma, Grade III, sponsored by David Baskin MD.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 62
- Enrollment target
- 1
- Study location
NCT03596086 is a Phase 1 study of Glioblastoma Multiforme and Astrocytoma, Grade III that is actively recruiting participants, run by David Baskin MD. The registered enrollment target is 62 participants, below the 96-participant average among 88 other Glioblastoma Multiforme trials with a reported enrollment target (35% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03596086, a Phase 1 study of Glioblastoma Multiforme and Astrocytoma, Grade III, is actively recruiting participants, sponsored by David Baskin MD.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 62 participants
- Enrollment target
- 1
- Study location
Study Summary
Study to assess the safety and efficacy of HSV-tk (gene therapy), valacyclovir, radiotherapy and chemotherapy in recurrent glioblastoma multiforme.
Conditions Studied
Interventions
- DRUG ADV/HSV-tk (gene therapy)
Study Locations (1)
Texas
- Houston Methodist Neurological Institute - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2017-12-11 |
| Est. Completion | 2025-12-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03596086
The ClinicalTrials.gov registry entry for NCT03596086 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 96-participant average among 88 other Glioblastoma Multiforme trials with a reported enrollment target (35% lower). The listed sponsor is David Baskin MD, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Glioblastoma Multiforme appearing as the primary indexed condition, and to 1 intervention - of which ADV/HSV-tk (gene therapy) is the first listed.
NCT03596086 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT03596086 about?
NCT03596086 is a clinical study titled "HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM". Study to assess the safety and efficacy of HSV-tk (gene therapy), valacyclovir, radiotherapy and chemotherapy in recurrent glioblastoma multiforme.
What is the current status of trial NCT03596086?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 62 participants. The study started on 2017-12-11. Estimated completion is 2025-12-30.
What conditions does trial NCT03596086 study?
This clinical trial studies the following conditions: Glioblastoma Multiforme, Astrocytoma, Grade III.
What interventions are being tested in trial NCT03596086?
The interventions under investigation include: ADV/HSV-tk (gene therapy) (DRUG).
Who is sponsoring clinical trial NCT03596086?
This trial is sponsored by David Baskin MD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03596086 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma Multiforme
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Trial of Anti-PD-1 Immunotherapy and Stereotactic Radiation in Patients With Recurrent Glioblastoma
RECRUITING · Phase 1
-
Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects
RECRUITING · Phase 1
-
Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age
RECRUITING · Phase 1
-
Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.
RECRUITING · Phase 1
-
HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
RECRUITING · Phase 1
-
Autologous CAR-T Cells Targeting B7-H3 in Recurrent or Refractory GBM CAR.B7-H3Tc
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.